A significant stepping stone in radiotherapy occurred with
the announcement by the therapeutic oncology company, RefleXion Medical.
RefleXion Medical received clearance from the U.S. Food and Drug Administration
(FDA) for three types of therapy; stereotactic body radiotherapy (SBRT),
stereotactic radiosurgery (SRS), and intensity-modulated radiotherapy (IMRT).
The groundbreaking new technology within the X1 machine will allow for more
precise tumor location capabilities that can combine high-quality CT imaging.
Within the X1 device, a linear accelerator offers technology that can rotate 60
times faster than standard linear devices. In this article, the CEO of
RefleXion Medical is hoping that the X1 machine will treat not only the early
stages of cancer but also offer thorough treatment solutions for those
suffering from the most advanced stages. The transition of this company from a
research-level, to now a commercial entity, has been a 10-year process. The
company comes full circle by offering a new form of treatment with
biology-guided radiotherapy (BgRT) into the market.
No comments:
Post a Comment